Literature DB >> 15247629

Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6).

Oliver von Richter1, Marià Pitarque, Cristina Rodríguez-Antona, Anna Testa, Roberto Mantovani, Mikael Oscarson, Magnus Ingelman-Sundberg.   

Abstract

OBJECTIVES: In humans, cytochrome P450 2A6 (CYP2A6) constitutes the principal nicotine C-oxidase. Several different polymorphic CYP2A6 gene variants are known which contribute to the highly variable expression of this enzyme among individuals. In this study we report a novel polymorphism located in the 5' flanking region (-745A > G) of the CYP2A6 gene disrupting a CCAAT box. METHODS AND
RESULTS: Electrophoretic mobility shift assays (EMSA) indicated that NF-YA is part of this nuclear protein complex. Chromatin immunoprecipitation revealed that NF-Y recognizes a region of the CYP2A6 5' flanking region located between -932 and -606. EMSA showed that out of the three CCAAT boxes in the CYP2A6 promoter, with CCAAT core sequences located between -839/-835, -748/-744, and -689/-685, only the one at -748/-744 was able to compete with the nuclear protein complex binding to the -748/-744 CCAAT box. Cotransfection experiments indicated that NF-Y acts as a positive regulatory element on CYP2A6 gene regulation. EMSA demonstrated that an NF-Y consensus oligonucleotide but not the -745A > G oligonucleotide competed efficiently with binding of the protein complex to the -748/-744 CCAAT box. Promoter activity of the -745A > G variant was significantly reduced to 78% relative to the wild-type allele in HepG2 cells transfected with luciferase reporter plasmids. Finally, haplotype analysis was carried out comprising the -745A > G variant in combination with all known CYP2A6 3' and 5' flanking single nucleotide polymorphisms: -1013A > G, -48T > G, and the CYP2A6/CYP2A7 3' flank conversion.
CONCLUSION: A new haplotype, CYP2A6*1H was identified, with allele frequencies of 3.1% in Swedish and 5.2% in Turkish populations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247629     DOI: 10.1097/00008571-200406000-00006

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  6 in total

1.  A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.

Authors:  A Joseph Bloom; Oscar Harari; Maribel Martinez; Xiaochun Zhang; Sandra A McDonald; Sharon E Murphy; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

2.  Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.

Authors:  A Joseph Bloom; Oscar Harari; Maribel Martinez; Pamela A F Madden; Nicholas G Martin; Grant W Montgomery; John P Rice; Sharon E Murphy; Laura J Bierut; Alison Goate
Journal:  Hum Mol Genet       Date:  2012-03-26       Impact factor: 6.150

3.  The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.

Authors:  Joseph Bloom; Anthony L Hinrichs; Jen C Wang; Linda B von Weymarn; Evan D Kharasch; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

4.  A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.

Authors:  Nael Al Koudsi; Jasjit S Ahluwalia; Shih-Ku Lin; Edward M Sellers; Rachel F Tyndale
Journal:  Pharmacogenomics J       Date:  2009-04-14       Impact factor: 3.550

Review 5.  Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Authors:  Luis A López-Flores; Gloria Pérez-Rubio; Ramcés Falfán-Valencia
Journal:  EXCLI J       Date:  2017-03-06       Impact factor: 4.068

6.  Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.

Authors:  Marijana Vujkovic; Scarlett L Bellamy; Athena F Zuppa; Marc R Gastonguay; Ganesh S Moorthy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Brian L Strom; Gregory P Bisson; Richard Aplenc; Robert Gross
Journal:  Pharmacogenomics J       Date:  2018-06-01       Impact factor: 3.550

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.